Field and laboratory fish tissue accumulation of the anti-convulsant drug carbamazepine.
Understanding the potential for human and veterinary pharmaceuticals to accumulate in the tissues of biota is a topic of increasing importance in the pharmaceutical risk assessment process. However, few data are available in the literature that compare the ability of laboratory bioconcentration studies to predict field tissue concentrations. To begin to address this data gap, bioconcentration factors (BCF) for carbamazepine (CBZ), a human anticonvulsant that modulates Na+ channels, were determined using laboratory experiments with Pimephales notatus and Ictalurus punctatus. These data were compared to field derived bioaccumulation factors (BAFs) for Oreochromis niloticus from the Denton, Texas Wastewater Treatment Plant. The 42 d kinetic BCFs (BCFk) for white muscle and liver of P. notatus were 1.9 and 4.6, respectively, while the white muscle, liver, brain, and plasma BCFk's of I. punctatus were 1.8, 1.5, 1.6, and 7.1, respectively. Field derived BAF values (2.5-3.8) for O. niloticus were similar to those derived in laboratory studies. Partitioning values between blood plasma and individual tissues were calculated for I. punctatus and O. niloticus, with the values indicating that tissue levels of carbamazepine are similar or slightly higher than plasma concentrations. Collectively these data suggest that the fish laboratory BCF and field derived BCF/BAF values for carbamazepine are similar and much lower than the European Union regulatory threshold of 2000 for designation of a "B" substance.